Badanie fazy 1/2 nad AOC 1020 u dorosłych z dystrofią mięśniową twarzowo-łopatkowo-ramieniową (FSHD)

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that causes muscle weakness, primarily affecting the face, shoulders, and upper arms. This study focuses on evaluating a new treatment called AOC 1020, which is a type of medication designed to target specific genetic components involved in FSHD. The treatment is administered as a powder for infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of the study is to assess the safety and tolerability of different doses of AOC 1020 in adults with FSHD. Participants will receive either the active treatment or a placebo, which is a substance with no active medication, to compare the effects. The study will monitor how the body processes the medication and its impact on muscle tissue over time.

Participants will be randomly assigned to receive either AOC 1020 or the placebo, and neither the participants nor the researchers will know who receives which treatment. This approach helps ensure unbiased results. The study will involve regular visits to the clinic for infusions and assessments, with the goal of understanding how the treatment affects the condition and its potential benefits for those with FSHD.